In the article “2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation” by Verma et al., published in the October 2014 issue of the Canadian Journal of Cardiology (Can J Cardiol 2014;30:1114-30), the authors wish to correct unfortunate errors that crept into the text:
- 1.In affiliation “i”, the city should be listed as “Halifax.”
- 2.Reference 36a should be added for the “EMBRACE trial,” at the end of page 1118: Gladstone DJ, Spring M, Dorian P, et al; for the EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med 2014;370:2467-77.
- 3.On page 1121, the following text incorrectly appears twice in Recommendation 15: “followed by therapeutic OAC for at least 4 weeks after cardioversion.”
- 4.On page 1122, in paragraph regarding “BRUISE Control trial,” above Recommendation 16, the text in parentheses should read “CHADS2 > 2,” not “CHADS2 ≥ 2.”
- 5.Renal function measurements repeatedly stated as GFR in the paper should be presented as CrCl, and renal function units stated as “mL/min/1.73 m2” should simply be mL/min.
We deeply apologize for these errors.
Published online: June 15, 2015
© 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- 2014 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial FibrillationCanadian Journal of CardiologyVol. 30Issue 10
- PreviewAtrial fibrillation (AF) is an extremely common clinical problem with an important population morbidity and mortality burden. The management of AF is complex and fraught with many uncertain and contentious issues, which are being addressed by extensive ongoing basic and clinical research. The Canadian Cardiovascular Society AF Guidelines Committee produced an extensive set of evidence-based AF management guidelines in 2010 and updated them in the areas of anticoagulation and rate/rhythm control in 2012.